Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia

被引:68
作者
Jethava, Y. S. [1 ]
Sica, S. [2 ]
Savani, B. [3 ]
Socola, F. [1 ]
Jagasia, M. [3 ]
Mohty, M. [4 ]
Nagler, A. [5 ,6 ]
Bacigalupo, A. [2 ]
机构
[1] Univ Arkansas Med Sci, Div Hematol, Dept Internal Med, 4301 W Markham St 508, Little Rock, AR 72205 USA
[2] Univ Cattolica Sacro Cuore, Inst Haematol, Rome, Italy
[3] Vanderbilt Univ Sch Med, Dept Hematol, Nashville, TN USA
[4] Hop St Antoine, Serv Hematol Clin & Therapie Cellulaire, Paris, France
[5] Chaim Sheba Med Ctr, Hematol Div, Ramat Gan, Israel
[6] Tel Aviv Univ, Ramat Gan, Israel
关键词
TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; BUSULFAN PLUS CYCLOPHOSPHAMIDE; ACUTE MYELOGENOUS LEUKEMIA; UNRELATED DONOR TRANSPLANTATION; ACUTE NONLYMPHOBLASTIC LEUKEMIA; COLONY-STIMULATING FACTOR; REDUCED-INTENSITY; MYELODYSPLASTIC SYNDROME;
D O I
10.1038/bmt.2017.83
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age. Relapse post allo-HSCT remains an important issue, especially for patients who undergo transplant with residual or refractory disease. In these patients, pre- and post-transplant interventions need to be considered.
引用
收藏
页码:1504 / 1511
页数:8
相关论文
共 68 条
[31]   Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation [J].
Lu, DP ;
Dong, LJ ;
Wu, T ;
Huang, XJ ;
Zhang, MJ ;
Han, W ;
Chen, H ;
Liu, DH ;
Gao, ZY ;
Chen, YH ;
Xu, LP ;
Zhang, YC ;
Ren, HY ;
Li, D ;
Liu, KY .
BLOOD, 2006, 107 (08) :3065-3073
[32]   Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor [J].
Michallet, Mauricette ;
Sobh, Mohamad ;
Milpied, Noel ;
Bay, Jacques-Olivier ;
Fuerst, Sabine ;
Harousseau, Jean-Luc ;
Mohty, Mohamad ;
Nicolini, Franck E. ;
Labussiere, Helene ;
Tedone, Nathalie ;
Morisset, Stephane ;
Vigouroux, Stephane ;
Baumgart, Joachim ;
Tabrizi, Reza ;
Blaise, Didier .
ANNALS OF HEMATOLOGY, 2012, 91 (08) :1289-1297
[33]   Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation [J].
Morris, Edward S. ;
MacDonald, Kelli P. A. ;
Kuns, Rachel D. ;
Morris, Helen M. ;
Banovic, Tatjana ;
Don, Alistair L. J. ;
Rowe, Vanessa ;
Wilson, Yana A. ;
Raffelt, Neil C. ;
Engwerda, Christian R. ;
Burman, Angela C. ;
Markey, Kate A. ;
Godfrey, Dale I. ;
Smyth, Mark J. ;
Hill, Geoffrey R. .
NATURE MEDICINE, 2009, 15 (04) :436-441
[34]   Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen-A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].
Nagler, Arnon ;
Rocha, Vanderson ;
Labopin, Myriam ;
Unal, Ali ;
Ben Othman, Tarek ;
Campos, Antonio ;
Volin, Liisa ;
Poire, Xavier ;
Aljurf, Mahmoud ;
Masszi, Tamas ;
Socie, Gerard ;
Sengelov, Henrik ;
Michallet, Mauricette ;
Passweg, Jakob ;
Veelken, Hendrik ;
Yakoub-Agha, Ibrahim ;
Shimoni, Avichai ;
Mohty, Mohamad .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3549-+
[35]   Busulphan in Blood and Marrow Transplantation: Dose, Route, Frequency and Role of Therapeutic Drug Monitoring [J].
Nath, Christa Ellen ;
Shaw, Peter John .
CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (01) :75-91
[36]   Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide [J].
O'Donnell, PV ;
Luznik, L ;
Jones, RJ ;
Vogelsang, GB ;
Leffell, MS ;
Phelps, M ;
Rhubart, P ;
Cowan, K ;
Piantadosi, S ;
Fuchs, EJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (07) :377-386
[37]   Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation [J].
Oran, Betul ;
Wagner, John E. ;
DeFor, Todd E. ;
Weisdorf, Daniel J. ;
Brunstein, Claudio G. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (09) :1327-1334
[38]   How I treat the older patient with acute myeloid leukemia [J].
Ossenkoppele, Gert ;
Lowenberg, Bob .
BLOOD, 2015, 125 (05) :767-774
[39]   131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission [J].
Pagel, JM ;
Appelbaum, FR ;
Eary, JF ;
Rajendran, J ;
Fisher, DR ;
Gooley, T ;
Ruffner, K ;
Nemecek, E ;
Sickle, E ;
Durack, L ;
Carreras, J ;
Horowitz, MM ;
Press, OW ;
Gopal, AK ;
Martin, PJ ;
Bernstein, ID ;
Matthews, DC .
BLOOD, 2006, 107 (05) :2184-2191
[40]   Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome [J].
Pagel, John M. ;
Gooley, Theodore A. ;
Rajendran, Joseph ;
Fisher, Darrell R. ;
Wilson, Wendy A. ;
Sandmaier, Brenda M. ;
Matthews, Dana C. ;
Deeg, H. Joachim ;
Gopal, Ajay K. ;
Martin, Paul J. ;
Storb, Rainer F. ;
Press, Oliver W. ;
Appelbaum, Frederick R. .
BLOOD, 2009, 114 (27) :5444-5453